Because the in silico parameters of ligand–target complex formation and DYRK/CLK inhibitory profiles differed for 1 and 2, we first compared the effects of each compound on RNA splicing in patient-derived GBM cells. This evidence concerns the gene CLK1 and glioblastoma.